![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/_processed_/csm_DKFZ_abcda82777.jpg)
Protein flags Car-T cells for digestion by NK cells
The protein B7H6, which is highly expressed on activated human T cells, can flag the cells for clearance by natural killer (NK) cells, weakening the...
![](/fileadmin/_processed_/csm_RNF31_Pub_domain__c__RCBS_protein_data_base_62ddf70879.jpg)
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
![](/fileadmin/Content/NewsAndStories/2024/SciRhom_01_2_80_.png)
SciRhom GmbH closes €63m Series A financing
SciRhom GmbH’s Series A financing was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners - new investor...
![](/fileadmin/_processed_/csm_quantro_747ee92cb9.png)
Quantro Therapeutics cashes in milestone payment from Boehringer Ingelheim
Austrian QUANTRO Therapeutics GmbH has reached a key milestone in its three year R&D and licence option collaboration with Boehringer...
![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_Iqvia-obesity_pipeline_0680784a7f.png)
AstraZeneca puts step into obesity market
SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a...